How Ketamine Spawned a $1.7 Billion J&J Blockbuster Drug

Spravato, the ketamine-derived nasal spray from Johnson & Johnson, was once seen as a long shot. It was difficult to deliver, heavily regulated and slow to catch on. Find out how it became a billion-dollar drug and part of a new model for treating depression. How J&J leveraged insurance to turn Spravato into a blockbuster depression drug. The $1.7 Billion Trip: https://www.bloomberg.com/features/2026-jjs-spravato-psychedelic-blockbuster-drug/ Like this video? Subscribe and turn on notifications so you don't ...